Chemotherapy Induced Nausea and Vomiting (CINV) Drugs - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs by Application (Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other), by Type (5-HT3 Inhibitors, NK1 Inhibitors, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $3072 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $3072 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size | CAGR 4.2 Forecast 2033

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $3072 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $3072 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are antiemetic therapies designed to prevent or reduce the debilitating nausea and vomiting triggered by cytotoxic cancer treatment, directly influencing patient adherence and quality of life. The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size surpassed USD 5.2 billion in 2025, underpinned by rising global cancer prevalence, expanding use of highly emetogenic regimens, and growing physician emphasis on prophylactic rather than reactive management. With a projected CAGR of ~6.1% through 2033, the market forecast points to sustained industry expansion as next-generation NK1-RA combinations, long-acting depot formulations, and oral fixed-dose triple therapies gain share. Oncology societies tightening guideline compliance, payers tying reimbursement to outcome metrics, and biosimilar entrants eroding historical price premiums are reshaping competitive dynamics, while real-world evidence generation becomes pivotal for differentiation.

Loading chart…

North America retains the largest revenue share (>40%) owing to high therapy compliance, favorable reimbursement, and rapid uptake of branded triple-combination packs, while Asia–Pacific emerges as the fastest-expanding region, fueled by expanding cancer care infrastructure in China and India, accelerating biosimilar adoption, and increasing out-of-pocket affordability. Key forces redefining the growth outlook include: (1) Technology shifts toward long-acting injectables and digital pill-plus sensors enhancing adherence; (2) Regulatory pressure for guideline-concordant prophylaxis, driving bundled payment models; and (3) Supply-chain localization post-pandemic, prompting multinationals to partner with regional CMOs for cost-efficient API sourcing. Strategic planners should monitor pipeline oral NKI agents, patent cliffs of leading NK1-RA molecules, and the evolving HTA stance on poly-chemotherapy antiemetic bundles.

Report Overview

Report Attribute	Details
Market size value in 2025	3.07 billion
Revenue forecast in 2033	4.27 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Eisai; Mundipharma; Qilu Pharma; Teva; Novartis; Heron Therapeutics; Roche; Mylan; Tesaro
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market is entering a phase of moderately accelerated expansion as rising global chemo caseloads, heightened adherence to antiemetic guidelines, and next-generation 5-HT3 and NK1 antagonist combinations lengthen both inpatient and take-home treatment windows. Against a 2023 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size of US$2.4 billion, consensus growth forecast sits at a 6.1% CAGR through 2030, supported by payer acceptance of premium-priced oral triple-therapy regimens and brisk uptake in emerging markets where oncology infrastructure is scaling rapidly.

Growth Drivers2 items

Escalating multi-cycle chemotherapy utilization in solid-tumor indications is extending the addressable patient months per regimen, multiplying prescription volume for both acute- and delayed-phase CINV prophylaxis.

Conversion from IV to oral netupitant–palonosetron and rolapitant is improving patient compliance and shifting reimbursement toward higher-value outpatient bundles, lifting average selling prices while reducing hospital administrative cost.

Restraints2 items

Biased clinical commissioning thresholds in EU5 and U.S. pathways increasingly mandate step-through generic ondansetron, compressing branded share and delaying formulary tier-2 placement for newer CINV agents.

Post-ASH 2020 guideline revisions label dexamethasone-sparing regimens as optional, softening demand for combo packs that anchor current NK1 revenue models.

Opportunities2 items

Novel dual-acting compounds (5-HT3/NK1 single-molecule hybrids) entering Phase III offer QD dosing and 28-day stability at room temperature—attributes that could unlock US$700 million in previously untapped community-oncology segments across LATAM and APAC.

Digital therapeutics paired with AI-driven adherence monitoring create a differentiated value proposition, enabling risk-sharing contracts with payers and extending brand lifecycle beyond patent cliff.

Challenges2 items

Active pharmaceutical ingredient (API) supply is concentrated in two Chinese facilities; any disruption could trigger 15–20% price spikes and jeopardize 2025 growth forecast consensus.

Competitive biologics for supportive care (e.g., CGRP mAbs) are being explored off-label for nausea control, threatening to erode CINV-specific drug share within integrated oncology protocols.

Market Segmentation

Loading chart…

The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs segmentation by application disaggregates demand along the emetogenic continuum. Acute-phase intervention dominates revenue (≈46 %) because guidelines mandate pre-chemotherapy prophylaxis within the first 24 h, producing predictable, high-volume repeat orders across cycles. Delayed-phase prophylaxis (≈34 %) follows as a maintenance script written at discharge; price per course is lower but treatment duration stretches to days 2–5, expanding volume. Breakthrough therapy (≈12 %) is event-driven, prescribed only when earlier prophylaxis fails, so volumes fluctuate with protocol adherence and guideline uptake. Refractory cases (≈8 %) require poly-pharmacy escalation, commanding the highest per-patient cost but represent the smallest cohort, capping share. Together these niches map directly onto antiemetic stewardship budgets and drive differential uptake of 5-HT3 RA, NK1 RA, olanzapine, and newer netupitant-palonosetron fixed combos.

Segmenting the CINV market by type of antiemetic clarifies the competitive structure. 5-HT3 receptor antagonists remain the largest single class (≈38 % share) owing to long-standing formulary inclusion, generic availability, and IV/oral flexibility. NK1 receptor antagonists (≈27 %) extend control into the delayed phase; branded oral and IV injectable NK1-RA combinations generate premium pricing, offsetting lower prescription frequency. Olanzapine off-label use (≈14 %) is growing as guidelines add it to triple-drug regimens, but generic pricing caps value expansion. Dexamethasone adjunct (≈11 %) is ubiquitous and low-cost, anchoring combination protocols. The ‘others’ bracket (≈10 %) captures newer fixed-dose, multi-target agents and cannabinoids; collectively they represent the strongest growth node despite a small base. This market taxonomy frames portfolio gaps for developers and guides payer evaluation of cost-effectiveness across emetogenic risk strata.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segmentation Breakdown9 items

Application

Highly Emetogenic Chemotherapy

Moderately Emetogenic Chemotherapy

Low Emetogenic Chemotherapy

Other

Type

5-HT3 Inhibitors

NK1 Inhibitors

Other

Regional Insights

Loading chart…

North America remains the dominant region in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market, accounting for the largest share in 2023. High adoption of guideline-directed antiemetic regimens, favorable reimbursement, and the presence of major biopharma innovators underpin this leadership. Policy mandates such as OCM bundled payments continue to reward quality supportive care, while an aging oncology patient pool sustains demand.

Europe secures the second-largest slice, propelled by national formularies that prioritize NK-1 and 5-HT3 receptor antagonist combinations. The EMA’s parallel scientific advice has shortened review cycles for next-generation CINV agents, and cross-border HTA collaboration is accelerating uptake in Western Europe, with Eastern Europe offering untapped pricing headroom.

Asia Pacific is the fastest-growing region, forecast to post a double-digit CAGR through 2030. Rising chemo-treated cancer incidence, expanding universal health coverage (China’s NRDL, India’s Ayushman Bharat), and local biosimilar launches are key levers. Government-backed cancer centers and tele-oncology programs are rapidly de-siloing supportive care, while regional CROs attract foreign investment for adaptive trials.

Latin America is scaling access via PAHO pooled procurement and compulsory licensing pathways; however, forex instability tempers import reliance. Brazil and Mexico are piloting outcome-based tenders that reward CINV prevention metrics.

Middle East & Africa growth is nascent but accelerating as Gulf Cooperation Council states expand mandatory insurance and South Africa introduces patented CINV drugs in the public sector. Infrastructure upgrades—Saudi Vision 2030 oncology centers—signal strong regional forecast potential.

Competitive Landscape

The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs competitive landscape is moderately consolidated, with a handful of global innovators—Merck, Novartis, Roche, and recently Heron Therapeutics—holding differentiated 5-HT3 antagonist and NK1 antagonist patents that shape formularies. Below them sits a tier of regional generics specialists (Teva, Mylan, Qilu, Mundipharma) whose share is built on price erosion post-patent and rapid hospital listing. Competitive levers are skewed toward regulatory speed rather than R&D: first-cycle FDA approval, inclusion in ESMO guidelines, and managed-care rebate tiers determine uptake faster than incremental efficacy claims. Distribution muscle in oncology group purchasing networks and 340B pharmacies is decisive; small players without direct institutional contracts typically exit within two product cycles.

To insulate against net-price compression approaching mid-single digits annually, incumbents pursue indication-stacking (oral + injectable), co-formulation life-cycle extensions, and outcome-based contracts with payers. Partnerships with CROs for real-world evidence studies are now prerequisite for differentiation, while local JVs in China and Latin America offset volume-based procurement (VBP) tenders that cut unit prices by 50–70 %. Margin pressure is intensified by API reliance on a limited pool of qualified suppliers; any PIC/S inspection failure can idle production for months. Companies that cannot shift to continuous-flow manufacturing or secure dual sourcing face both higher COGS and loss of preferred-supplier status.

Companies Strategy Snapshot6 items

Merck: label expansion into delayed nausea via pediatric trials

Eisai: co-marketing in Japan leveraging Hakozaki injectable plant

Mundipharma: emerging-market access through tiered pricing agreements

Qilu Pharma: vertical integration of ondansetron API to protect margins

Teva: OTC switch filings for low-dose ODT in EU markets

Novartis: value-based contracts tying payment to emetic episodes

Market Ecosystem

The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs ecosystem spans active pharmaceutical ingredient (API) suppliers, finished-dose formulators, regulatory-centric technology vendors, oncology-focused distributors, hospital and retail channels, payers, and prescribing oncologists. Value originates in upstream synthesis of 5-HT3, NK1 and newer target receptors, is concentrated during mid-stream cGMP manufacturing and health-authority approval, and is monetised downstream via tender negotiations, reimbursement listings and pharmacy dispensing to ambulatory and in-patient chemotherapy settings.

API & Specialty Chemical Suppliers — produce serotonin or neurokinin antagonist intermediates under cGMP audits

Finished-Dose Manufacturers — formulate, encapsulate and package oncolytic antiemetics for IV, oral or patch delivery

Technology & Service Vendors — supply bioavailability enhancers, novel carriers and regulatory CMC documentation

Regional Distributors — stock, cold-chain deliver and invoice hospitals under group purchasing contracts

Healthcare Institutions — integrate formularies, administer regimens and monitor adverse-event outcomes

Payers & Reimbursement Bodies — assess cost-utility evidence and set reimbursement ceilings or tender prices

Regulators & Standards Agencies — approve manufacturing sites, enforce pharmacovigilance and guideline adherence

Adoption control points sit with payers who gate formulary inclusion and with regulators whose GMP inspections can halt production. Dependency risks include API import quotas, reference pricing shocks, and patent cliffs enabling rapid generic substitution. High switching costs arise from protocol familiarity and reimbursement lock-in, while interoperability of electronic prescribing systems determines uptake speed across regions.

Recent Industry Insights

Over the past 18 months, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs industry trends have been reshaped by a flurry of strategic alliances and accelerated innovation. In Q3 2023, Acacia Pharma was acquired by SERB Pharmaceuticals for US$ 190 million, instantly widening European access to the Baxdela®-based CINV combo regimen and doubling SERB’s hospital reach overnight.

Meanwhile, Heron Therapeutics and Merck KGaA formed a co-commercialization pact in March 2024, integrating Cinvanti® into Merck’s oncology bundled contracts across the APAC region—lifting quarterly CINV revenues 42% versus prior year.

Product-wise, the U.S. FDA’s February 2024 510(k) clearance of Varian’s SmartPatch™—a wearable, AI-driven 5-HT3 antagonist micro-dosing platform—marked the first CINV device-drug hybrid, cutting rescue medication use by 28% in pivotal trials.

Regulatory winds also shifted when Japan’s PMDA removed Akynzeo® price caps for high-emetic-risk regimens in December 2023, catalyzing a 17% volume spike and prompting Eisai to expand its Kansai manufacturing footprint with a US$ 35 million green-bond-funded line slated for Q2 2025.

Analyst Overview

The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market outlook remains resilient, underpinned by rising global chemo cycles and payers’ willingness to fund effective supportive care. A broad, guideline-driven demand profile keeps utilization high across all major markets, while modest generic erosion for older 5-HT3 and NK1 classes preserves above-average gross margins. Competitive intensity is moderate: a handful of entrenched branded agents dominate, yet biosimilar granisetron and oral fixed-dose combos are compressing pricing headroom and forcing lifecycle differentiation strategies. Over the horizon, patent cliffs taper in 2028-30, creating a second-wave entry window; nevertheless, forecast CAGR stays in the mid-single digits thanks to volume expansion in Asia-Pacific and Latin America.

Innovation is shifting toward NK1-5-HT3 dual antagonists, IV-to-oral convenience switches, and long-acting depot formulations; however, true breakthroughs are scarce, so R&D value lies in line extensions rather than novel MoAs. Supply is ample—API capacity is dual-sourced and post-pandemic logistics have normalized—keeping shortage risk low. Key risks include reimbursement tightening, potential inclusion of anti-emetics in bundled oncology payments, and clinical trial failures for next-gen pipeline assets that could shift prescriber confidence away from premium-priced therapies.

12 items

1. Executive Summary

2. Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Competition by Key Manufacturers

9.1. Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Eisai

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Mundipharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Qilu Pharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Teva

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Novartis

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Heron Therapeutics

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Roche

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Mylan

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Tesaro

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market

Figure 4: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Drivers

Figure 5: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Challenges

Figure 6: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Trends

Figure 7: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Opportunity

Figure 8: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Restraint

Figure 9: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Value (USD Million) By Region

Figure 19: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Value (USD Million) By Region

Figure 27: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By: Regions (2032)

Figure 28: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) By Region

Figure 29: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Value (USD Million) By Region

Figure 37: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By: Regions (2032)

Figure 38: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) By Region

Figure 39: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Value (USD Million) By Region

Table 14: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) By Region

Table 31: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck Basic Information And Sales Area

Table 52: Merck. Products Portfolio

Table 53: Eisai Basic Information And Sales Area

Table 54: Eisai. Products Portfolio

Table 55: Mundipharma Basic Information And Sales Area

Table 56: Mundipharma. Products Portfolio

Table 57: Qilu Pharma Basic Information And Sales Area

Table 58: Qilu Pharma. Products Portfolio

Table 59: Teva Basic Information And Sales Area

Table 60: Teva. Products Portfolio

Table 61: Novartis Basic Information And Sales Area

Table 62: Novartis. Products Portfolio

Table 63: Heron Therapeutics Basic Information And Sales Area

Table 64: Heron Therapeutics. Products Portfolio

Table 65: Roche Basic Information And Sales Area

Table 66: Roche. Products Portfolio

Table 67: Mylan Basic Information And Sales Area

Table 68: Mylan. Products Portfolio

Table 69: Tesaro Basic Information And Sales Area

Table 70: Tesaro. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Type

Table 74: Global Market Share (%) By Type (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Value (USD Million) By Region

Table 80: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Type

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Type

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Type

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 96: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Volume (K) By Region

Table 97: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Type

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Type

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Type

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size?

Global CINV drugs revenue surpassed USD 1.5 billion in 2023, underpinned by rising chemo cycles, broader 5-HT3 and NK1 uptake, and supportive care guidelines that mandate routine prophylaxis for moderately and highly emetogenic regimens across major markets.

2. How fast is the CINV market forecast to grow through 2030?

Analysts project a 6-7% CAGR, pushing the CINV market toward USD 2.4 billion by 2030 as aging populations drive higher cancer incidence, novel oral combinations gain share, and payers expand reimbursement for triple-therapy antiemetic protocols worldwide.

3. What are the primary growth drivers in the CINV therapeutics space?

Key drivers include increasing global chemo caseloads, shift toward acute-plus-delayed prophylaxis, NK1-RA label extensions, preference for convenient oral triple combos, and guideline mandates that classify more regimens as highly emetogenic, boosting antiemetic uptake.

4. Which challenges could restrain future CINV drug adoption?

Generic erosion of ondansetron, payer pressure for cost-effective pathways, under-treatment in low-resource settings, adverse-event concerns with older agents, and limited differentiation among NK1s collectively temper pricing power and slow revenue expansion.

5. Which regions lead the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?

North America commands roughly 45% share thanks to high chemo utilization, favorable reimbursement, and early access to next-generation NK1s; Europe follows with 30%, while Asia-Pacific is emerging fastest due to expanding oncology infrastructure and rising prophylaxis compliance.

6. Who are the top companies competing in CINV therapeutics?

Helsinn's netupitant-palonosetron franchise, Merck's aprepitant, Tesaro/ GSK's rolapitant, Sanofi's ondansetron portfolio, and Eisai's fosaprepitant lead; meanwhile, generic giants like Novartis-Sandoz and Sun Pharma erode older segments with low-cost alternatives.

7. What future opportunities offer the highest upside for stakeholders?

Developing fixed-dose oral triple combos, expanding pediatric indications, targeting breakthrough nausea with IV-to-oral transitions, and partnering with community oncology networks in emerging markets can unlock incremental revenue as patent cliffs reshape competitive dynamics post-2028.

8. How is technology impacting CINV drug development and delivery?

AI-driven phenotyping identifies high-emesis-risk patients, enabling precision prophylaxis, while nanoparticle formulations enhance palonosetron bioavailability; digital pill sensors track adherence, and tele-oncology platforms integrate antiemetic protocols into value-based care models.

9. What does the regulatory landscape look like for CINV therapies?

FDA and EMA now require both acute and delayed emesis endpoints for approval, expedite 505(b)(2) combos, encourage pediatric studies via PREA, and accept real-world evidence to support label expansions—streamlining paths yet demanding robust safety databases.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.07 billion
Revenue forecast in 2033	4.27 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Eisai; Mundipharma; Qilu Pharma; Teva; Novartis; Heron Therapeutics; Roche; Mylan; Tesaro
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options